Edition:
United States

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

1.79USD
3:59pm EST
Change (% chg)

$-0.10 (-5.29%)
Prev Close
$1.89
Open
$1.83
Day's High
$1.85
Day's Low
$1.76
Volume
113,931
Avg. Vol
126,468
52-wk High
$6.58
52-wk Low
$1.02

Latest Key Developments (Source: Significant Developments)

Axovant Sciences Says Frank Torti Appointed Chairman Of The Board
Tuesday, 2 Oct 2018 04:47pm EDT 

Oct 2 (Reuters) - Axovant Sciences Ltd ::SAYS FRANK TORTI APPOINTED CHAIRMAN OF THE BOARD.AXOVANT SCIENCES - EFFECTIVE SEPTEMBER 26, VIVEK RAMASWAMY RESIGNED AS A MEMBER AND CHAIRPERSON OF BOARD.  Full Article

Axovant Sciences Says Entered Sales Agreement With Cowen And Co
Friday, 22 Jun 2018 05:38pm EDT 

June 22 (Reuters) - Axovant Sciences Ltd ::AXOVANT SCIENCES LTD - ON JUNE 22, 2018, CO ENTERED INTO A SALES AGREEMENT WITH COWEN AND COMPANY, LLC - SEC FILING.AXOVANT SCIENCES LTD - AGREEMENT TO SELL CO'S COMMON SHARES HAVING AGGREGATE OFFERING PRICE OF UP TO $75 MILLION FROM TIME TO TIME.  Full Article

Axovant Says Gavin Corcoran, Chief Medical Officer Of Allergan, To Join Co As EVP Of R&D
Tuesday, 29 May 2018 07:00am EDT 

May 29 (Reuters) - Axovant Sciences Ltd ::AXOVANT STRENGTHENS MANAGEMENT TEAM AND COMPLETES ORGANIZATIONAL RESTRUCTURING IN PREPARATION FOR PIPELINE EXPANSION.AXOVANT SCIENCES LTD - AS PART OF RESTRUCTURING PLAN, INTERNAL HEADCOUNT HAS DECREASED BY APPROXIMATELY 43%.AXOVANT SCIENCES LTD - GAVIN CORCORAN, CURRENT CHIEF MEDICAL OFFICER OF ALLERGAN PLC, TO JOIN AXOVANT AS EVP OF RESEARCH AND DEVELOPMENT.  Full Article

BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study
Wednesday, 6 Dec 2017 05:23pm EST 

Corrects headline to say the final protocol was submitted for dementia with Lewy bodies study, not Parkinson's study:AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT.AXOVANT SCIENCES LTD SAYS SUBMITTED PROTOCOL THAT DESIGNATES ADAS-COG & CIBIC+ AS CO-SECONDARY ENDPOINTS FOR PHASE 2B HEADWAY STUDY - SEC FILING.  Full Article

Axovant announces second fiscal quarter results
Thursday, 2 Nov 2017 04:30pm EDT 

Nov 2 (Reuters) - Axovant Sciences Ltd :Axovant announces second fiscal quarter financial results and corporate updates.Q2 loss per share $0.64.Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.Axovant Sciences Ltd - ‍Axovant held cash of $235.4 million at september 30, 2017​.  Full Article

Axovant sciences says exploring nelotanserin as treatment for Rem sleep behavior disorder
Monday, 13 Feb 2017 07:00am EST 

Axovant Sciences Ltd : Axovant sciences announces preliminary results from interim analysis of phase 2 study testing investigational drug nelotanserin in Lewy body dementia patients . Axovant expects to initiate phase 3 program in second half of 2017 . Plans to expand study recruitment to further explore updrs findings and expects final results in mid-2017 . Axovant Sciences-in interim analysis, secondary endpoints did not demonstrate statistically significant differences for nelotanserin relative to placebo .Axovant Sciences-is exploring nelotanserin as a potential treatment for rem sleep behavior disorder (RBD) in patients with dementia with Lewy bodies.  Full Article